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Abstract
Background: B-type natriuretic peptide (BNP), a member of the natriuretic peptide family, is a cardiac-derived
secretory hormone with natriuretic, diuretic, and vasorelaxant activities. Intraabdominal fat accumulation is
associated with atherosclerotic cardiovascular diseases and cardiac dysfunction. Circulating BNP levels are relatively
low (within the normal limits) in obesity and the metabolic syndrome. However, the relationship between plasma
BNP levels and visceral fat accumulation in general population has not been reported. The present study analyzed
the relationships between plasma BNP levels and various clinical variables, including insulin, visceral and
subcutaneous fat area (VFA and SFA, respectively), in normal Japanese men.
Methods: The study (Victor-J study) subjects were consecutive 500 Japanese male workers, who underwent a
health checkup and were measured VFA and SFA by computed tomography.
Results: Age-adjusted simple linear regression analysis showed that log-BNP correlated positively with HDL-
cholesterol, and negatively with VFA, log-immunoreactive insulin (IRI), log-triglyceride, and LDL-cholesterol, but not
body mass index or SFA. Stepwise multiple regression analysis identified log-IRI and HDL-cholesterol as significant
determinants of log-BNP. Subjects with IRI ≥5.5 μIU/mL had lower plasma BNP levels than those with IRI < 5.5 μIU/
mL, irrespective of obesity (body mass index, cutoff value 25 kg/m
2), visceral fat accumulation (VFA, cutoff value
100 cm
2) and subcutaneous fat accumulation (SFA, cutoff value 128 cm
2).
Conclusions: Our study showed that hyperinsulinemia correlated with low levels of plasma BNP in general men,
irrespective of fat distribution.
Trial registration: UMIN 000004318.
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Background
B-type natriuretic peptide (BNP), a member of the
natriuretic peptide (NP) family, is a cardiac-derived
secretory hormone with natriuretic, diuretic, and vasore-
laxant activities [1,2]. Plasma BNP level correlates with
the severity of heart failure, and is clinically used as a
marker of cardiac dysfunction [3]. Evidence suggests
that high BNP levels regulate endogenous antagonism of
vasoconstriction, the salt- and water-retaining system
that acts to prevent a rise in blood pressure, and plasma
volume expansion through direct natriuresis, diuresis,
and vasodilation.
Visceral fat accumulation correlated closely with systo-
lic blood pressure [4], and is also related to the develop-
ment of cardiac dysfunction [5]. However, circulating
NPs levels are relatively low (within the normal limits) in
obesity [6-11]. It has been suggested that obese subjects
have a “natriuretic handicap”, with a reduced NPs
response to cardiac wall stress. Low NPs levels may con-
tribute to the pathophysiology of cardiac dysfunction in
visceral adiposity. The present study analyzed the rela-
tionships between plasma BNP levels and various clinical
variables, including insulin, visceral and subcutaneous fat
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men.
Methods
Participants
The study subjects were consecutive 500 Japanese male
employees, who underwent a health checkup in year
2010 at Hitachi Ltd, Ibaraki Prefecture, including com-
p u t e dt o m o g r a p h y( C T ) .T h ep r e s e n ts t u d yw a s
approved by the human ethics committees of the
National Center for Global Health and Medicine, Osaka
University and Hitachi Health Care Center. Written
informed consent was obtained from all subjects. This
trial (Victor-J study) is registered with the University
Hospital Medical Information Network (#UMIN
000004318)
https://upload.umin.ac.jp/cgi-openbin/ctr/ctr.cgi?func-
tion=brows&action=brows&type=summary&recpt-
no=R000005173&lang uage=E.
Anthropometry and laboratory measurements
Height and weight were measured in standing position.
Body mass index (BMI) was calculated and expressed in
kg/m
2. Blood pressure was measured in a sitting posi-
tion with a standard mercury sphygmomanometer on
the right or left arm after the subjects had rested for at
least 5 minutes. VFA and SFA were computed and mea-
sured automatically using commercial software on a CT
scan taken at the umbilical level in supine position [120
kV, 400 mAsec, section thickness of 5-10 mm, field of
view of 400 mm, window width of 800- 1,000 Houns-
field units]. Venous blood samples were collected in the
morning after overnight fast for measurements of creati-
nine, hemoglobin A1c (HbA1c), HDL-cholesterol, LDL-
cholesterol, triglyceride, glucose, and immunoreactive
insulin (IRI). The value for HbA1c (%) is estimated as
National Glycohemoglobin Standardization Program
(NGSP) equivalent value (%) calculated by the formula
HbA1c (%) = HbA1c (Japan Diabetes Society [JDS],%) +
0.4%. Plasma BNP concentrations were measured with
specific immunoradiometric assay for human BNP (BNP
kit, Shionogi, Osaka, Japan, normal range; < 18.4 pg/mL,
intracoefficients of variation (CV); 2.7-9.6%, inter-CV
5.6-11.8%, range [2.0-2,000 pg/mL]).
Statistical analysis
Data are presented as mean ± SD (Tables) or mean ±
SEM (Figure). Stepwise multiple regression analysis was
first conducted to identify those parameters that signifi-
cantly contributed to log-BNP, and parameters with F
value > 4.0 were subsequently entered into the regression
analysis as independent variables. The subjects were
divided into four groups according to; (analysis 1) BMI
(cutoff value 25 kg/m
2;o b e s i t y )a n dI R I( c u t o f fv a l u e5 . 5
μIU/mL; median value), (analysis 2) VFA (cutoff value
100 cm
2; visceral fat accumulation) and IRI (cutoff value
5.5 μIU/mL; median value), (analysis 3) SFA (cutoff value
128 cm
2; median value) and IRI (cutoff value 5.5 μIU/
mL; median value). Differences among groups were com-
pared by one- or two-way analysis of variance (ANOVA)
with Fisher’s protected least significant difference test for
multiple-group analysis or unpaired Student’s t-test for
experiments involving only two groups. In all cases, p
values < 0.05 were considered statistically significant. All
analyses were performed with the JMP Statistical Discov-
ery Software 8.0 (SAS Institute, Cary, NC).
Results
Characteristics of subjects enrolled in the present study
The baseline characteristics of the subjects who underwent
a health checkup are listed in Table 1. Only 12.4% (n = 62)
were hyper-BNPemic (above the normal range; upper limit
of normal range; ≥18.4 pg/mL), and 70.2% of the subjects
(n = 351) had visceral fat accumulation (VFA ≥100 cm
2).
Correlation analysis between plasma BNP levels and
measured parameters
Table 2 lists the correlation coefficients for the relation-
ship between BNP and various clinical parameters. Data
Table 1 Baseline characteristics of male subjects
participating in the present study (n = 500)
mean ± SD
[range or n (%)]
Age, years 55 ± 9 (30-74)
Body mass index (BMI), kg/m
2 24.2 ± 3.0 (14.8-36.5)
Visceral fat area (VFA), cm
2 127 ± 54 (3-294)
Subcutaneous fat area (SFA), cm
2 136 ± 56 (5-361)
Blood glucose, mg/dL 110 ± 18 (78-284)
Fasting immunoreactive insulin (IRI), μIU/mL 6.7 ± 4.5 (0.6-42.3)
HbA1c (NGSP),% 5.8 ± 0.6 (4.6-10.2)
Systolic blood pressure (SBP), mmHg 123 ± 12 (91-174)
Diastolic blood pressure (DBP), mmHg 78 ± 8 (47-100)
Triglyceride, mg/dL 140 ± 95 (35-871)
High-density lipoprotein cholesterol
(HDL-cholesterol), mg/dL
56 ± 13 (32-97)
Low-density lipoprotein cholesterol
(LDL-cholesterol), mg/dL
122 ± 28 (39-199)
Estimated glomerular filtration rate
(eGFR), mL/min
73.7 ± 12.8 (41.9-128.5)
Plasma B-type natriuretic peptide (BNP), pg/mL 10.8 ± 13.0 (2.0-159)
Smoking (none/ex-/current-smoker) 131/240/129
Diabetes mellitus (under medication) 24 (17)
Hypertension (under medication) 116 (115)
Dyslipidemia (under medication) 63 (59)
Past history of CAD/CVD 5/3
CAD, coronary artery disease, CVD, Cerebrovascular disease
Glomerular filtration rate was estimated by eGFR = 194 × serum creatinine
-
1.094 ×a g e
-0.287
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therefore were log-transformed before analysis. Age-
adjusted simple linear regression analysis showed that
log-BNP correlated positively with HDL-cholesterol
(Figure 1B), and negatively with VFA, log-IRI (Figure
1B), log-triglyceride, and LDL-cholesterol, but not BMI
or SFA. Stepwise multiple regression analysis identified
HDL-cholesterol and log-IRI as significant and indepen-
dent determinants of log-BNP.
Comparisons of clinical features including plasma BNP
levels according to obesity and fat distribution
Subjects with IRI ≥5.5 μIU/mL had lower plasma BNP
levels than those with IRI < 5.5 μIU/mL, irrespective of
obesity (analysis 1, Table 3), visceral fat accumulation
(analysis 2, Table 4), and subcutaneous fat accumulation
(analysis 3, Table 5) (Figure 2). These results suggest
that hyperinsulinemia correlates with low levels of
plasma BNP, irrespective of fat distribution.
Discussion
Our cross-sectional study of Japanese male subjects
demonstrated for the first time that hyperinsulinemia cor-
related with low levels of plasma BNP, irrespective of fat
distribution. The present study also found that HDL-cho-
lesterol was a significant determinant of log-BNP. Although
Wang et al. demonstrated that reduced HDL-cholesterol
was associated with lower plasma BNP levels by multivari-
able analysis [12], the mechanism remains unclear.
As the mechanisms, we should consider the effect of
hyperinsulinemia on BNP production and catabolism.
There is controversy on whether or not hyperinsuline-
mia directly suppresses BNP production [13,14]. NPs,
through the activation of the biologically active mem-
brane guanylate-cyclase-linked NPR-1 has a potent lipo-
lytic effect in human adipocytes via a cGMP-dependent
mechanism [15] and activation of hormone-sensitive
lipases [16,17]. Metabolism of NPs is regulated by two
degradative pathways; uptake by the clearance receptor,
natriuretic peptide receptor-3 (NPR-3) and hydrolysis by
NEP [18]. Our and the other groups previously demon-
strated that, 1) NPR-1, NPR-2 and NPR-3 mRNAs are
expressed in the adipose tissues, however mRNA level
of NEP is relatively low [19], and 2) lower NPR-1
mRNA levels and higher NPR-3 mRNA levels in the
adipose tissues of ob/ob mice [19] or in the adipose tis-
sues and muscle of diet-induced mice [20], models of
hyperinsulinemia, compared to lean mice. Plasma NEP
levels were higher in diet-induced mice and tissue NEP
was increased in mesenteric fat in diet-induced mice,
compared with normal-diet mice [21]. The effect of
insulin on NEP has not been reported. Taken together,
dysregulation of two degradative pathways under
Table 2 Results of simple and stepwise multiple
regression analyses for log-BNP
Simple (non-
adjusted)
Simple
(age-adjusted)
Multiple
rp rp F value
Age 0.3688 < 0.0001 - -
BMI -0.1225 0.0069 -0.0080 0.0559
VFA -0.0707 0.1037 -0.0010 0.0048 0.007
SFA -0.1342 0.0025 -0.0004 0.0816
Blood glucose 0.0837 0.0579 0.0003 0.7088
Log-IRI -0.2408 < 0.0001 -0.2430 < 0.0001 11.771
HbA1c 0.0894 0.0527 0.0050 0.8280
Systolic blood pressure 0.1304 0.0031 0.0010 0.2595
Diastolic blood
pressure
-0.0134 0.7650 0.0020 0.2815
Log-triglyceride -0.1517 0.0007 -0.1480 0.0079 0.385
HDL-cholesterol 0.2098 < 0.0001 0.0040 < 0.0001 6.437
LDL-cholesterol -0.1414 0.0014 -0.0010 0.0088 2.377
eGFR -0.1304 0.0035 -0.0004 0.6988
Smoking (ex-+current-) -0.0088 0.8442 -0.0090 0.7565
Data of BNP, IRI and triglyceride levels showed skewed distribution, and
therefore were log-transformed before analysis. Multiple; [adopted factors:
age, VFA, log-IRI, log-triglyceride, HDL-cholesterol, LDL-cholesterol]
Figure 1 A histogram of plasma BNP levels and correlation between log-IRI, HDL-cholesterol and log-BNP. Pearson’s correlation analysis
was used to examine the relationships between log-IRI, HDL-cholesterol and log-BNP. Regression curve with 95% confidence interval of
predicted mean together with reference lines indicating baseline (0% change)
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low circulating BNP levels.
Amino-terminal pro-BNP (NT-proBNP), which is co-
secreted in equimolar amounts with BNP from the car-
diac ventricle, is also well-established as a diagnostic
marker in heart failure [22,23]. Surgical weight loss with
reduced insulin levels was associated with increases in
NT-proBNP [24]. Women with gestational diabetes mel-
litus under insulin therapy had lower circulating NT-
proBNP levels than those under medical nutrition
therapy or healthy pregnancies [25]. These results sug-
gest that circulating levels of NT-proBNP as well as
BNP may be regulated by insulin. However, clearance of
plasma NT-proBNP occurred across kidney, liver, mus-
culoskeletal, and head and neck tissue [26], differ from
plasma BNP cleared by NPRs and NEP. Further experi-
mental and clinical studies including both BNP and NT-
proBNP are required. Improvement of hyperinsulinemia
may reduce plasma volume and thus lower blood pres-
sure through the increase in plasma NPs levels. This
Table 3 Comparison of clinical features between subjects without and with obesity (BMI cutoff value 25 kg/m
2) and
hyperinsulinemia (IRI cutoff value 5.5 μIU/mL; median value) (Analysis 1) (n = 500)
BMI < 25 kg/m
2 BMI ≥ 25 kg/m
2
IRI < 5.5 μIU/mL IRI ≥ 5.5 μIU/mL IRI < 5.5 μIU/mL IRI ≥ 5.5 μIU/mL
Age, years 55 ± 9 54 ± 10 55 ± 8 53 ± 9
BMI, kg/m
2 22.1 ± 1.8 23.2 ± 1.2* 26.2 ± 1.5* 27.6 ± 2.4
†§
VFA, cm
2 94 ± 44 131 ± 40* 144 ± 36* 171 ± 45
†§
SFA, cm
2 103 ± 36 127 ± 33* 154 ± 42* 191 ± 58
†§
Blood glucose, mg/dL 106 ± 15 114 ± 20* 114 ± 33* 111 ± 13
Fasting IRI, μIU/mL 3.8 ± 1.1 7.8 ± 2.6* 4.5 ± 0.8* 11.0 ± 5.8
†§
HbA1c (NGSP),% 5.7 ± 0.5 5.8 ± 0.7* 6.0 ± 0.9* 5.8 ± 0.5
SBP, mmHg 120 ± 12 124 ± 11* 126 ± 11* 125 ± 10
DBP, mmHg 76 ± 8 79 ± 7* 78 ± 14 80 ± 7
Triglyceride, mg/dL 117 ± 88 148 ± 99* 171 ± 112* 161 ± 89
HDL-cholesterol, mg/dL 61 ± 13 55 ± 12* 54 ± 8* 51 ± 11
†
LDL-cholesterol, mg/dL 117 ± 28 121 ± 27 124 ± 30 131 ± 27
†
eGFR, mL/min 74 ± 13 76 ± 13 74 ± 11 71 ± 13
†
Data are mean ± SD
*p < 0.01, compared to with BMI < 25 kg/m
2 and IRI < 5.5 μIU/mL
†p < 0.01, compared to with BMI < 25 kg/m
2 and IRI ≥ 5.5 μIU/mL
§p < 0.01 compared to with BMI ≥ 25 kg/m
2 and IRI < 5.5 μIU/mL
Table 4 Comparison of clinical features between subjects without and with visceral fat accumulation (VFA cutoff value
100 cm
2) and hyperinsulinemia (IRI cutoff value 5.5 μIU/mL; median value) (Analysis 2) (n = 500)
VFA < 100 cm
2 VFA ≥ 100 cm
2
IRI < 5.5 μIU/mL IRI ≥ 5.5 μIU/mL IRI < 5.5 μIU/mL IRI ≥ 5.5 μIU/mL
Age, years 53 ± 11 47 ± 12* 56 ± 8* 54 ± 9
†§
BMI, kg/m
2 21.6 ± 2.0 23.1 ± 2.5* 23.9 ± 2.0* 25.9 ± 2.8
†§
VFA, cm
2 63 ± 26 72 ± 24 139 ± 28* 162 ± 40
†§
SFA, cm
2 92 ± 38 114 ± 58* 129 ± 37* 167 ± 55
†§
Blood glucose, mg/dL 104 ± 14 110 ± 14 110 ± 23* 113 ± 17
Fasting IRI, μIU/mL 3.6 ± 1.1 7.1 ± 1.4* 4.2 ± 0.9* 9.8 ± 5.0
†§
HbA1c (NGSP),% 5.6 ± 0.5 5.6 ± 0.5 5.8 ± 0.6* 5.9 ± 0.6
SBP, mmHg 118 ± 12 121 ± 13 123 ± 11* 125 ± 10
DBP, mmHg 75 ± 9 77 ± 7 78 ± 10* 80 ± 7
§
Triglyceride, mg/dL 101 ± 63 108 ± 49 149 ± 111* 160 ± 96
†
HDL-cholesterol, mg/dL 62 ± 13 57 ± 10 58 ± 13* 52 ± 12
†§
LDL-cholesterol, mg/dL 115 ± 29 124 ± 25 121 ± 28 127 ± 28
eGFR, mL/min 76 ± 12 79 ± 13 73 ± 12 73 ± 13
†
Data are mean ± SD
*p < 0.01, compared to with VFA < 100 cm
2 and IRI < 5.5 μIU/mL
†p < 0.01, compared to with VFA < 100 cm
2 and IRI ≥ 5.5 μIU/mL
§p < 0.01 compared to with VFA ≥ 100 cm
2 and IRI < 5.5 μIU/mL
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jects with hyperinsulinemia.
Conclusion
In conclusion, hyperinsulinemia correlated with low
levels of plasma BNP in general men, irrespective of fat
distribution.
Study limitations
Several limitations of this study must be considered. First,
this is a cross-sectional study, making it difficult to estab-
lish a cause-effect relationship. Further prospective studies
should be conducted in the future to analyze this
relationship. Second, the results may not be applicable to
females or non-Japanese populations. Finally, in the pre-
sent study, drug information was based on information
provided by the subjects or their relatives. The current
study may include the effects of use of various medications
for diabetes, hypertension and dyslipidemia. Further stu-
dies that include untreated patients need to be conducted.
Abbreviations
BNP: B-type natriuretic peptide; CT: Computed tomography; IRI:
Immunoreactive insulin; NEP: Neutral endopeptidase; NP: Natriuretic peptide;
NPR: Natriuretic peptide receptor; SFA: Subcutaneous fat area; VFA: Visceral
fat area.
Table 5 Comparison of clinical features between subjects without and with subcutaneous fat accumulation (SFA cutoff
value 128 cm
2; median value) and hyperinsulinemia (IRI cutoff value 5.5 μIU/mL; median value) (Analysis 3) (n = 500)
SFA < 128 cm
2 SFA ≥128 cm
2
IRI < 5.5 μIU/mL IRI ≥5.5 μIU/mL IRI < 5.5 μIU/mL IRI ≥5.5 μIU/mL
Age, years 55 ± 9 55 ± 10 55 ± 9 52 ± 9
†
BMI, kg/m
2 21.9 ± 1.9 23.4 ± 1.9* 24.7 ± 1.9* 26.6 ± 2.8
†§
VFA, cm
2 88 ± 43 128 ± 48* 131 ± 41* 164 ± 43
†§
SFA, cm
2 91 ± 27 104 ± 21* 157 ± 31* 187 ± 50
†§
Blood glucose, mg/dL 106 ± 20 115 ± 19* 108 ± 16 111 ± 16
Fasting IRI, μIU/mL 3.7 ± 1.1 7.4 ± 1.9* 4.4 ± 0.9* 10.4 ± 5.4
†§
HbA1c (NGSP),% 5.7 ± 0.5 5.9 ± 0.7* 5.8 ± 0.6 5.8 ± 0.5
SBP, mmHg 120 ± 13 126 ± 13* 123 ± 11* 124 ± 10
DBP, mmHg 76 ± 8 79 ± 7* 78 ± 11 80 ± 7
Triglyceride, mg/dL 117 ± 81 157 ± 114* 145 ± 117* 153 ± 83
HDL-cholesterol, mg/dL 62 ± 13 55 ± 11* 56 ± 12* 51 ± 12
†§
LDL-cholesterol, mg/dL 119 ± 31 124 ± 30 118 ± 24 128 ± 26
§
eGFR, mL/min 75 ± 13 74 ± 15 73 ± 11 73 ± 12
Data are mean ± SD
*p < 0.01, compared to with SFA < 128 cm
2 and IRI < 5.5 μIU/mL
†p < 0.01, compared to with SFA < 128 cm
2 and IRI ≥5.5 μIU/mL
§p < 0.01 compared to with SFA ≥128 cm
2 and IRI < 5.5 μIU/mL
Figure 2 Comparison of plasma BNP levels between subjects without and with hyperinsulinemia (IRI cutoff value 5.5 μIU/mL; median
value), and obesity (BMI cutoff value 25 kg/m
2, Analysis 1), visceral fat accumulation (VFA cutoff value 100 cm
2, Analysis 2) or
subcutaneous fat accumulation (SFA cutoff value 128 cm
2; median value, Analysis 3). Data are mean ± SEM.
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